AusperBio, AHB-137, Chronic Hepatitis B, HBV, Antisense Oligonucleotide, ASO Therapy, AASLD 2026, The Liver Meeting, Functional Cure, Hepatitis B Treatment, Clinical Development, Phase 3 Trial

San Francisco, California, U.S., October 7, 2026 AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. have announced that two...